DUBLIN, Ireland, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today the closing of a previously announced underwritten public offering of its ordinary shares owned by Elan Science One Limited (the "Selling Shareholder"), an indirect wholly owned subsidiary of Perrigo Company plc ("Perrigo"). The offering of 3,182,253 ordinary shares of Prothena included 415,076 ordinary shares that were sold pursuant to the underwriters' option to purchase additional shares, which was exercised in full prior to closing. The ordinary shares were sold at a price to the public of $26.00 per ordinary share, before the underwriting discount. As a result of the full exercise of the underwriters' option, the Selling Shareholder and Perrigo no longer own any ordinary shares of Prothena.
Help employers find you! Check out all the jobs and post your resume.
